AVXL
ANAVEX LIFE SCIENCES CORP.
NASDAQ · Healthcare · Biotechnology · US
$2.42
+0.41%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$2.42
From 52W high−75.70%
Volume920361.00
Market cap$224.33M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$2.42
From 52W high
−75.70%
Volume
920361.00
Market cap
$224.33M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.9x
P/E (TTM)
—
RSI (14)
34.6
MomentumView details →
1D Return
+0.41%
YTD Return
−31.88%
SummaryUpdated Jun 1, 2026
Anavex Life Sciences Corp. (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in New York. The company has been publicly traded since 2006 and focuses exclusively on developing treatments for central nervous system (CNS) diseases, particularly neurodegenerative and neuropsychiatric conditions. Anavex has built its pipeline around sigma receptor modulators, with its lead drug candidate <b>blarcamesine</b> (ANAVEX 2-73) currently in Phase III trials for Alzheimer's disease and having recently received marketing authorization application acceptance from the European Medicines Agency.
Similar companies
Latest newsMore news →
Glass Lewis recommended that Anavex Life Sciences stockholders vote the GOLD universal proxy card, supporting PVG Asset Management's call for change by backing two of PVG's director nominees and opposing two incumbent director nominees including the board's current chair.3d agoInstitutional Shareholder Services recommended that Anavex Life Sciences stockholders vote for all six of the company's director nominees on the white proxy card at the 2026 Annual Meeting of Stockholders.6d agoAnavex Life Sciences announced regulatory progress for its lead drug blarcamesine in Q3 2026.26d ago